T2 Biosystems Inc (TTOO) 2024 Q1 法說會逐字稿

Greetings. Welcome to the T2 Biosystems Inc. First Quarter 2024 earnings conference call. (Operator Instructions) Please note this conference is being recorded. I will now turn the conference over to your host, Philip Taylor. You may begin.

Thank you, operator. I'd like to remind everyone that comments made by management today and answers to questions will include forward looking statements. Those include statements related to T2 Biosystems' future financial and operating results and plans for developing and marketing new products. Forward-looking statements are based on estimates and assumptions as of today and are subject to risks and uncertainties that may cause actual results to differ materially from those expressed or implied by these statements, including the risks and uncertainties described in T2 Biosystems' annual report on Form 10 K filed with the SEC on April first, 2024 and other filings the company makes with the SEC from time to time the Company undertakes no obligation to publicly update or revise any forward-looking statements except as required by law.

With that, I would like to turn the call over to Chairman and CEO, John Sperzel. John

Tthank you for joining our first quarter 2024 Results Call. I will start with an update on our NASDAQ compliance plan and our capital plans, and then discuss our first quarter progress across our three corporate priorities. Before turning the call over to John Sprague, our Chief Financial Officer, we will review our financial results and outlook for 2024. I will then provide closing remarks and open the call for questions and answers.

On March 12th, 2024, we announced that the NASDAQ hearings panel had granted our request for continued listing on the NASDAQ stock market, subject to the Company, demonstrating compliance with NASDAQ market value of listed securities or market value requirement as set forth in NASDAQ Listing Rule 55 50 b. to the rule on or before May 20th, 2024. The rule requires that the Company maintain a closing market value of at least $35 million for a minimum of 10 consecutive business days.

As I outlined in our recent investor update call, an important part of our NASDAQ compliance plan included the conversion of debt to equity in April 2024, the company converted $15 million of its term loan with entities affiliated with CRG servicing LLC or CRG, our lender into T2 Biosystems equity. Today, the company announced the conversion of an additional $15 million of its term loan with CRG for a total debt to equity conversion of $30 million in the past 30 days, which we believe significantly improves the probability of meeting the NASDAQ listing requirements. In the past 12 months, we have reduced our debt and associated quarterly interest payments by approximately 80%. Earlier today, we filed an S-1 registration statement that included our plan to raise up to $10 million in capital through the issuance of new securities. We believe the Company is at an inflection point, transforming from an internally focused research and development company to an externally focused commercial company. And this capital is necessary for general working capital and to help us achieve our goals, including increasing our sepsis product sales, launching the T. two Lyme panel and advancing the T. two Resistance Panel. Simultaneously, we intend to reduce operating costs, reduce inventory and increased production volumes. Today, we are applying our technology to sepsis, Lyme disease and bioterrorism. These three areas shared the need for rapid pathogen detection and faster targeted antimicrobial treatments are core opportunity. Sepsis continues to impose an enormous human and economic toll, such as is the leading cause of death in US hospitals claiming the lives of 270,000 Americans annually with an additional 80,000 who die and hospice each year. Sepsis also represents the leading expense of U.S. hospitalization costing our healthcare system, an estimated $62 billion annually.

Lastly, sepsis is the leading cause of a 30 day US hospital readmission with 19% of sepsis survivors re hospitalized within 30 days and 40% within 90 days. Rapid detection of sepsis causing pathogens is crucial as mortality risk increases by up to 8%, but each hour of delayed targeted antimicrobial treatments.

As we've discussed, T2 Biosystems has developed and commercialized the only FDA-cleared products able to detect sepsis, causing pathogens directly from blood in just three to five hours without the need to wait days for a positive blood culture, competitive products like those marketed by bioMerieux, BD and accelerate first require a positive blood culture which can take days. So when those competitors claim that they can produce species identification or antibiotic susceptibility or AST. results in one to three hours. It is after they wait one to five days for a positive blood culture. And when blood culture produces false negative results due to lack of sensitivity for inhibition due to prior antimicrobial treatment. Those culture dependent technologies provide little to no value. A meta analysis of 14 controlled studies published in a peer-reviewed medical journal compare T2 Biosystems' sepsis test to blood culture based diagnostics and showed that T2 Biosystems products provided faster time to detection. For example, species identification 77 hours faster faster targeted therapy. For example, patients testing positive with T2 Biosystems receiving targeted antimicrobial therapy 42 hours faster and finally, reduced length of stay. For example, five fewer days in the ICU and 4.8 fewer days in the hospital, thanks to strong efforts of our team.

During the first quarter of 2024, we made considerable progress across our three corporate priorities, accelerating our sales, enhancing our operations and advancing our pipeline.

Starting with our first corporate priority, accelerating our sales in the first quarter of 2024, our team achieved sepsis product revenue of $2.1 million, representing growth of 25% compared to the prior year period. Our team also achieved sequential quarterly growth of 23% compared to the fourth quarter of 2023. The growth in the first quarter was led by sales of our T2Candida Panel globally and sales of our T. two Resistance Panel internationally, we added eight T. two Dx Instrument contracts, continuing to grow our installed base with five sold in international markets and three in the U.S. market. We're seeing strong momentum in the US market, including four hospital go-lives during the first quarter from prior account closes, we're focused on growing revenue in our current U.S. hospital accounts through improved focus and coordination between medical affairs, sales and field applications. The strong global performance of T2Bacteria Panel during the quarter is also encouraging as we gained FDA clearance in February of this year to expand T2Bacteria Panel to include the detection of as needed backed by money. I we expect even further utilization of the T2Bacteria Panel moving forward.

During the quarter, we further expanded our international distribution network in the Middle East by signing a new distribution agreement in Qatar, which includes the T. two Dx instrument, the T2Bacteria Panel T2Candida Panel and the T. two Resistance Panel Qatar's national sepsis program is a collaboration between the Ministry of Public Health and leading medical centers that guides the national sepsis prevention efforts in the pre Qatar's. Strong focus on sepsis care is demonstrated by sepsis mortality rates among the best in the world and a regular national sepsis symposium. The introduction of the T. two Dx Instrument and sepsis test panels into Qatar will allow rapid detection of sepsis causing pathogens and antibiotic resistance genes in hours instead of days, enabling clinicians to achieve faster targeted therapy. We expect to continue to expand into new geographies and broaden our international distribution network throughout 2024. We also extended our existing multiyear capital equipment supplier agreement with Vizient, the largest group purchasing organization in the United States until March 31st, 2025. This extension ensures that members continue to have access to the benefit from contracted pricing for our T. two Dx Instrument T2Bacteria Panel and T2Candida Panel this move emphasizes the demand among hospitals for more efficient, rapid diagnostics that enable faster targeted therapy. It also highlights the significant value proposition our products offer to patients suspected of sepsis generating compelling clinical data that demonstrates the value of our technology as a core part of our strategy.

During the first quarter of 2024, we announced the publication of the strongest evidence to date in support of the T. two Resistance Panel in a real-world hospital setting published in the Journal of Clinical Microbiology study highlights high accuracy for the T. two Resistance Panel, faster detection times and the impact of faster test results on clinical innovations based on T2 sepsis test results. This compelling data not only strengthens our position in CE mark adopting countries where the T. two Resistance Panel is already available, but also sets the stage for our entry into the US market.

New data was also presented at mid 2024, showing improved patient outcomes with the T2Candida Panel compared to blood culture-based diagnostics and the ability for the T2Bacteria Panel to detect persistent Staph aureus infections better than blood culture.

Finally, to advance our commercial opportunities for the T2 biothreat panel, we've entered into an agreement with Dr. Robin Robinson to serve as a strategic adviser. Dr. Robinson has significant experience and expertise leading US government entities in the areas of medical countermeasures and biodefense, including serving as Director of the Biomedical Advanced Research and Development Authority for Barta and the deputy assistant secretary in the Office of the Assistant Secretary of preparedness in response for Aspyr within the U.S. Department of Health and Human Services. We believe Dr. Robinson's vast network across multiple US government agencies including CDC, Asper, Barta Department of Defense and National Institutes of Health, coupled with its expertise in medical countermeasures and biodefense will be invaluable as we pursue government contracts to procure the T2 biothreat panel and protect our nation from the consequences of deliberate or accidental exposure to BioThrax. It's important to note that T2 biothreat panel sales are not in our current 2024 revenue guidance. So potential sales during 2024 represents upside to that guide.

Moving to our second corporate priority, enhancing our operations. We're committed to improving the profitability of the business. This requires continued product sales growth and reduced operating costs and improved cost to product revenue, all of which we are prioritizing. We're pleased to have eliminated the product backorder and we've been working to reduce inventory levels as an operational priority. We're driving improvements in manufacturing efficiency as we scale production, and we're working to improve product gross margins from an operating expense perspective, we will continue to balance investing appropriately in commercial and development resources to support future growth while being prudent with expenses to preserve cash.

Moving to our third priority advancing our pipeline. We have three tests in our pipeline, including the UST. two Resistance Panel, the T. two Lyme panel and the Candida auris test, each of which has received Breakthrough Device designation from the U.S. Food and Drug Administration. These three tests or test panels share a critical requirement for rapid pathogen detection and targeted antimicrobial treat the T. two Resistance Panel is a direct from blood molecular diagnostic tests that runs on the FDA-cleared T. two Dx Instrument and simultaneously detects 13 antibiotic resistance genes in just three to five hours without the need to wait days for a positive blood culture. We believe the T. two Resistance Panel will be a significant catalyst to drive broader adoption of our T. two Dx Instrument and our T2Bacteria Panel. As I mentioned earlier, in March, we issued a press release to announce the results of a new study that was published in the Journal of Clinical Microbiology, highlighting the performance and clinical benefits of the teacher resistance panel. The prospective study included 59 patients at two sites and intended to determine the clinical sensitivity time to detection and clinical impact of the T. two Resistance Panel compared to blood culture and conventional microbiology methods highlights included high accuracy. The T. two Resistance Panel demonstrated clinical sensitivity of 94.7% and specificity adjudicated of 97.4%. This is consistent with the clinical performance of our two FDA-cleared sepsis test panels, the T2Bacteria Panel and the T2Candida Panel rapid turnaround time. T. two Resistance Panel results were available on average in 4.4 hours compared to 58.3 hours with blood culture based methods. The T. two Resistance Panel provided a 92% improvement in time to result compared to blood culture based diagnostics that is 4.4 hours versus 2.2 days. And finally, clinical impact. There were 49 clinical interventions in 24 of the 59 patients resulting in 17 antibiotic escalations and 32 discontinuations of unnecessary antibiotics. The use of the T. two Resistance Panel led to a change in antibiotic therapy for 41% of the patients in this study as those patients were on the wrong or unnecessary antibiotics. These results demonstrated the strongest clinical impact of the T. two Resistance Panel to date in a real-world hospital setting. We believe this performance data demonstrates the enormous potential of this unique and highly differentiated product to reduce cost, improve patient outcomes and reduce the threat of antibiotic resistance. We expect this to be a catalyst for greater adoption of the T. two Resistance panels in countries where we currently market under CE Mark. We also believe the international experience with direct from blood detection of antibiotic resistance genes is an important precursor through our launch in the U.S. market. As a reminder, we plan to submit a five 10 K premarket notification to the U.S. Food and Drug Administration for FDA during the third quarter of 2024, and we previously received Breakthrough Device Designation from the FDA, which were prior provide for a prioritized FDA review upon submission. The T. two Lyme panel is a direct from blood molecular diagnostic test designed for the early detection of Verallia Bergdorf for the bacterium that causes Lyme disease in the United States. Lyme disease is a leading vector-borne disease in America with an estimated 3.4 million tests performed each year. The current diagnostic process is a two tiered antibody test algorithm that relies on the presence of antibodies and can only be used accurately four to eight weeks after infection. If left untreated, the bacteria may spread throughout the body become much harder to eradicate and treat effectively. Although early symptoms of Lyme disease are similar to the flu. Broadly, Oberdorfer eye infections can lead to chronic debilitating disease to address this critical unmet need. We have developed an extremely sensitive diagnostic test for the detection of early Lyme disease with an analytical sensitivity that is in line with our FDA-cleared subsystem. We believe our test will detect Lyme disease within the first 30 days of infection compared to antibody tests that can take 30 to 60 days after infection. As I mentioned previously, we plan to launch our T. two Lyme panel as a laboratory-developed test or LDT during the third quarter of 2024. And we believe there are numerous potential advantages of launching this panel in this format, including faster time to market, higher test throughput and stronger product contribution margins. Importantly, in an LDT format, we can run the test without the T. two Dx instrument, which can provide the potential to process hundreds of Lyme tests per day. Because the individual components of our underlying technology can be leveraged to process a higher volume of samples given the LDT format does not require the T. two Dx instrument or the costs associated with a cartridge, we expect to realize strong product contribution margins. Our market research confirms that reference laboratories often charge greater than $250 for two tiered antibody line tests and greater than $250 for PCR Lyme tests. Our ultimate objective is to provide early line disease results to major U.S. reference laboratories. We believe we can utilize their strong retail networks to collect patient samples, which would allow us to provide testing to line patients across the country. These samples would then be sent to our LDT partner performed the T. two Lyme panel in their lab, as I mentioned, with T2 biothreat, it is important to note that T. two Lyme panel sales are also not in our current 2024 revenue guidance. So any potential sales during 2024 represents upside to that guide. Our Candida auris test is a direct from blood molecular diagnostic test designed to detect Candida auris species in just three to five hours without the need to wait days for a positive blood culture. We believe the addition of a Candida auris test will strengthen the value proposition of our T2Candida Panel and lead to increased adoption. Candida auris is a multi drug resistant fungal pathogen that has a mortality rate up to 60% and is recognized as a serious global health threat by the CDC and the World Health Organization. Cdc estimates the costs associated with U.S. fungal diseases are as high as $48 billion annually and has called on public health professionals to help lower the burden of fungal disease by continuing to raise awareness of the life-saving benefits of early detection and proper treatment Candida species are a major contributor to morbidity and mortality in hospitalized children and present a significant burden to the U.S. health care system with a mean increased hospital length of stay of 21 days and an estimated $92,000 in excess hospital costs for children with invasive candidiasis. A 2022 Journal of Clinical Microbiology study conducted at Deno Gold Zoo hospital in Rome, Italy found that pediatric patients suspected of a fungal bloodstream infections that were tested with the T2Candida Panel received species identification results 121.8 hours faster compared to blood culture based diagnostics.

Finally, we're also pursuing claims of our FDA-cleared T2Candida Panel and T2Bacteria Panel to include pediatric testing in December 2023 we submitted a five 10 K premarket notification to the FDA to expand the use of the T2Candida panel to include pediatric testing, and we expect to submit a 5-10K premarket notification to the FDA to expand the use of the T2Bacteria Panel to include pediatric testing during 2024.

With that, I'll now turn the call over to John Sprague to provide a detailed update on our first quarter financial results. John?

Thank you, John. First Quarter 2024 revenues were $2.1 million, all from sepsis product sales, a 25% increase compared to the prior year period; and sequential growth of 23% compared to the fourth quarter of 2023, led by T2Candida and T2 Resistance sales. First quarter 2024 cost of product revenue was $4.2 million, a 5% increase compared to the prior year period, driven by sales volume. Research and development expenses were $3.7 million, a 17% decrease compared to the prior year period, driven by decreased BARDA contract activities.

Selling, general and administrative expenses were $6.7 million, an 8% decrease compared to the prior year period, driven by decreased headcount. First Quarter 2024 net loss was $13.5 million or $2.66 per share compared to a first quarter 2023 net loss of $18 million, $131.77 per share. Cash and cash equivalents were $6.2 million as of the end of the first quarter 2024, and we raised $2.2 million in net proceeds from ATM sales in the quarter.

The CRG debt conversion has reduced our debt and interest expense by almost 80% compared to a year ago. We continue to expect total sepsis product revenues to grow between 49% and 64% to $10 million to $11 million in 2024 over 2023. And this target excludes any potential sales from T2 biothreat or T. two Lyme tests.

Thank you. And back to John Sperzel for closing remarks.

It's an extremely exciting time for the company as we've been taking measures to significantly reduce our debt, strengthen our balance sheet and position the Company for sustained growth. We are nearing four catalysts that we expect to be growth drivers. One, the T. two Lyme panel, which means we may launch sooner than anticipated via a partnership to the T2 biothreat panel, which we are pursuing initial sales to government agencies and have engaged a U.S. government expert three, the T2Candida panel to include pediatric testing, which is pending FDA five 10 K clearance and for the UST. two Resistance Panel, which we expect to submit for FDA five, 10 K clearance during the third quarter of 2024.

With that, I'd like to turn the call back to the operator to open the line for questions. Operator?

(Operator Instructions) Kyle Mikson, Canaccord.

Hey, guys, thanks for the questions and congrats on a good quarter. So the MTV. by the area was strong. You said, I think that benefited from the FDA expansion in February of this year. Can you or Jon, can you just talk a little bit more about like the quantitative impact from that expansion that test the some panel there, some this quarter and what exit rates look like in March, maybe in what we could, how we should think about the contribution going forward.

So I'll ask John Sprague to talk about the second part, but I'll certainly take the first part, Kyle. We're excited to get the FDA clearance to add as needed factor to our T2Bacteria panel that adds six target. Those six targets now take our our coverage to approximately 75% of what is typically seen in a bacterial bloodstream infection.

So while sometimes we get blowback about we only detect six targets. Those six targets comprise the overwhelming majority of bacterial bloodstream infections and adding that six target, it added approximately 5% additional coverage and it's the 10th most common bacterial pathogen seen in the ICU.

It has a mortality rate between 35% and 45%. So it's an important one to add and it is certainly drawn on demand and we expect to continue to again.

Was there anything else that you guys want to add to that? Or is that bulk of the answer.

Kyle, I think that covers it.

Sounds good. Guys, the cost reduction measures that you were talking about that I guess have been started recently or the other kind of seeing what their ongoing ones, the ones that become more tangible. I guess it's a little bit hard to kind of understand, given the revenue base is it has shifted year over year and things like that. So the burns all that, yes, it can be misleading. But when there's some ones that kind of flow through into the P&L and when could and I think physical gross margin for that to flip positive would be interesting to hear anything about that kind of near term.

I think you'll see improvements on a sequential quarterly basis. Our guide is between $10 million and $11 million. As John and I both mentioned, that does not include any sales of T2 biothreat or T. two Lyme and it ramps up from Q1 to Q2 to Q3 to Q4. So we'll get better overhead absorption and that will drive improved costs as well as the measures that were taken internally to control costs, reduce inventory, improve product gross margin.

Got you. And maybe just expand on that note, just expand on the CIV. on the kind of the the aspect of the Lyme panel being now just like an LDT for the time being that's a higher margin, given it doesn't have to use the T. two Dx Instrument So does that kind of it does look a benefit kind of going forward, tourism that is not super material. Just hard. Just challenging to understand like how real that really benefit that benefit really could be on margins.

What we think the long-term opportunity is a substantial opportunity. Today, there are 3.4 million Lyme tests performed our understanding from our market research is that PCR type tests, which by the way, the ones that are out there in the market are not very sensitive at all, continue to grow. And so we think the opportunity for a high-quality molecular diagnostic test that can detect Lyme in the first 30 days could have significant market appeal, command a premium price. The reason we're launching it initially as a lab-developed test. And we're certainly not ruling out a future FDA five, 10 K submission.

It's because we can get to market faster. We can address what we believe will be important throughput requirements by testing of instruments, and we don't need the cost associated with the cartridge.

So we think we can get higher throughput and we can command a better product contribution margin. And as I said in the prepared remarks, there's a good chance we launch ahead of schedule through an LDT partner.

And then did you discuss the FDA approval pathway for that for the Lyme panel, I guess, has that changed since the business update like it was like in March?

It hasn't changed from our perspective.

Certainly the FDA came out with their ruling on LDTs, which we don't think has any near-term impact related to our strategy to launch initially as an LDT, we have a perfect track record with the FDA every time we've made an FDA five 10 K submission. We have received clearance. We're not going to jeopardize that. We already have FDA breakthrough device designation for the T. two Lyme panel and we think launching as an LDT is going to help us collect data. And at the time we decide to pursue FDA 5-10K clearance, we'll be ready.

Let me ask another one for have off. The on. Barda is hasn't been in the model for for a couple of quarters be. Is there any like global research coverage opportunities programs that you are in the pipeline and are in the works that you're aware of? Is there any interest among various countries and governments to sort of it's more research and services that could benefit to possibly, but could that be a tailwind over time?

Absolutely. And so we've talked publicly about Candida auris.

And so every time we talk to a customer almost without exception about our T2Candida Panel. We are asked about the addition of Candida auris, including at the Actimid conference in our booth regularly over the last week or so and so we think we're on the right track in adding Candida auris to our T2Candida Panel on the test itself has FDA breakthrough device designation, and that's an area where we think there will be funding to help us get that over the goal line of sort of non-dilutive grant base type funding. There may also be that type of funding for adding additional targets on tick-borne panel. That's something we're also exploring in the early stages.

Now I think we have no further questions in queue. I will now turn the call over to John Sperzel for closing remarks.

Thank you very much for joining our Q1 earnings call. We appreciate your support and we look forward to updating you next quarter. Have a great afternoon.

This concludes today's conference and you may disconnect your lines at this time. Thank you for your participation.